Headline:Potassium Nitrate‘s Efficacy in Heart Failure Fails to Meet Expectations
Subheadline: Despite increasing nitric oxide levels, potassium nitrate’s impact on exercise capacity and quality of life in heart failure patients with preserved ejection fraction is limited.
Article:
In a recent clinical study, the administration of potassium nitrate (KNO3) failed to significantly improve exercise capacity or quality of life in patients with heart failure with preserved ejection fraction (HFpEF), despite elevating nitric oxide levels in the blood. The study raises questions about the therapeutic benefits of potassium nitrate for this patient population.
Study Design
The study, a multi-center crossover trial conducted in three U.S. centers, included 84 symptomatic HFpEF patients with an average age of 68. Sixty-nine percent were women, and 76% were Caucasian. Most participants were obese (with an average BMI of 36.22) and had associated conditions such as hypertension, diabetes, and sleep apnea.
Participants were randomly assigned to receive either 6 mmol of KNO3 or 6 mmol of potassium chloride (KCl) three times daily for six weeks, with a one-week washout period between treatments. At the end of each treatment phase, patients underwent an incremental cardiopulmonary exercise test using a supine cycle ergometer to evaluate exercise capacity.
Primary and Secondary Objectives
The primary objectives of the study were to assess the difference in peak oxygen uptake and work done during the exercise test. Secondary objectives included quality of life, left ventricular systolic and diastolic function, systemic vasodilatory reserve during exercise, and parameters related to arterial pulse loading.
Lack of Significant Improvements
While KNO3 administration significantly increased plasma nitrite/nitrate levels (418.44 μM versus 40.11 μM with KCl; P < 0.001), it did not result in significant improvements in primary objectives. Peak oxygen uptake and total work done during the exercise test did not differ significantly between KNO3 and KCl treatments. Furthermore, quality of life did not improve with KNO3 administration.
However, KNO3 administration did lead to a significant reduction in peak exercise mean arterial pressure compared to KCl (122.5 mm Hg versus 127.6 mm Hg; P = 0.04). Nevertheless, other measures, including vasodilatory reserve and changes in resting or post-standing blood pressure, did not show significant differences.
Safety Profile
Overall, KNO3 administration was generally well-tolerated, with most adverse effects being mild. Gastrointestinal problems were the most frequently reported side effects, but they did not result in serious complications or treatment discontinuation.
Conclusion and Implications
The study concludes that chronic KNO3 administration does not improve exercise capacity or quality of life in HFpEF patients, even though it increases nitric oxide metabolites. Authors suggest that while KNO3 may hold potential in certain areas, it is not an efficient therapeutic option for enhancing exercise performance or quality of life in this patient population.
Further research may be necessary to explore other therapeutic options for improving outcomes in HFpEF patients.
